ADC Therapeutics SA
BiotechADC Therapeutics SA is a biotechnology company focused on Oncology, Gastroenterology.
FDA Novel Drug Designations
(2021)See 1 novel approval →
ADC Therapeutics SA at a Glance
- Fast trial execution (34 months median completion)
ADC Therapeutics SA's Key Drugs
ADC Therapeutics SA's core commercial portfolio centers on ZYNLONTA, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
ADC Therapeutics SA's Recent FDA Approvals
New NDA/BLA approvals for ADC Therapeutics SA over the last two years — novel drugs only, excluding generics and label supplements.
ADC Therapeutics SA's Therapeutic Areas
ADC Therapeutics SA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ADC Therapeutics SA's Top Competitors
ADC Therapeutics SA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ADC Therapeutics SA Pipeline Snapshot
ADC Therapeutics SA has 20 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 4 Phase 2 and 15 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZYNLONTA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: 34 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-04-23
- Latest
- 2026-02-20
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges